Can Endoscopic Appearance, Selective Cytology, and Pathological Sampling During Ureteroscopy Accurately Predict Tumor Grade of Upper-Tract Urothelial Carcinoma?
Journal
Rambam Maimonides medical journal
ISSN: 2076-9172
Titre abrégé: Rambam Maimonides Med J
Pays: Israel
ID NLM: 101538065
Informations de publication
Date de publication:
27 Jan 2022
27 Jan 2022
Historique:
entrez:
28
1
2022
pubmed:
29
1
2022
medline:
29
1
2022
Statut:
epublish
Résumé
This study examined the reliability of the various parameters obtained in diagnostic ureteroscopy for upper-tract urothelial carcinoma (UTUC) in predicting the degree of differentiation in the final pathological report after radical nephroureterectomy (RNU). We conducted a retrospective review of patients undergoing RNU at a single tertiary hospital between 2000 and 2020. Only patients who underwent preoperative diagnostic ureteroscopy (URS) were included. The results of urine selective cytology, endoscopic appearance of the tumor, and biopsy taken during ureteroscopy were compared to the final pathological report. In total, 111 patients underwent RNU. A preliminary URS was performed in 54. According to endoscopic appearance, 40% of the "solid"-looking tumors were high grade (HG), while 52% of those with a papillary appearance were low grade (LG). Positive cytology predicted HG tumors in 86% of cases. However, 42% of patients with negative cytology had HG disease. The biopsies acquired during URS showed that HG disease findings matched the final pathology in 75% of cases. However, 25% of patients noted as being HG, based on URS biopsies, were noted to have LG disease based on nephroureterectomy biopsies. Full analyses revealed that 40% of the cases diagnosed as LG based on the URS biopsies actually had HG disease. Direct tumor observation of papillary lesions, negative cytology, and biopsies indicating LG disease are of low predictive value for classifying the actual degree of tumor differentiation. No single test can accurately rule out HG disease. In light of the rising use of neo-adjuvant chemotherapy in UTUC, a reliable predictive model should be developed that accurately discriminates between HG and LG disease.
Identifiants
pubmed: 35089121
pii: RMMJ.10459
doi: 10.5041/RMMJ.10459
pmc: PMC8798584
doi:
Types de publication
Journal Article
Langues
eng
Références
Transl Androl Urol. 2016 Oct;5(5):636-647
pubmed: 27785420
Urology. 2018 Jul;117:89-94
pubmed: 29630955
Eur Urol Focus. 2018 Dec;4(6):946-953
pubmed: 28753881
BJU Int. 2012 Dec;110(11):1608-17
pubmed: 22564677
BJU Int. 2019 Feb 23;:
pubmed: 30801918
Eur Urol. 2018 Jan;73(1):111-122
pubmed: 28867446
J Urol. 2018 Jun;199(6):1440-1445
pubmed: 29427584
J Urol. 2018 Jul;200(1):68-73
pubmed: 29307680
J Urol. 1976 Dec;116(6):781-3
pubmed: 1003651
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Clin Genitourin Cancer. 2018 Dec;16(6):e1237-e1242
pubmed: 30217764
J Urol. 2000 Jan;163(1):52-5
pubmed: 10604312
J Urol. 1986 Aug;136(2):383-5
pubmed: 3735500
Front Oncol. 2019 Mar 21;9:157
pubmed: 30949449
J Urol. 1997 Jan;157(1):33-7
pubmed: 8976209
Urology. 2003 Jun;61(6):1146-50
pubmed: 12809884
J Urol. 1989 Jun;141(6):1298-301
pubmed: 2724425
Urology. 2007 Aug;70(2):252-6
pubmed: 17826484
Urology. 2004 Apr;63(4):647-50; discussion 650
pubmed: 15072870
Urology. 2019 Jul;129:146-152
pubmed: 30930207
J Urol. 1990 Jun;143(6):1196-200
pubmed: 2188017
J Urol. 2001 Feb;165(2):600-11
pubmed: 11176445
Cancer. 2010 Jul 1;116(13):3127-34
pubmed: 20564621